Article Text

Download PDFPDF
Cohort study
The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases
  1. Rebecca B Perkins1,
  2. Cindy L Christiansen2
  1. 1Department of Obstetrics and Gynecology, Boston University School of Medicine/Boston Medical Center, Boston, Massachusetts, USA
  2. 2Department of Health Policy and Management, Boston University School of Health, Boston, Massachusetts, USA
  1. Correspondence to : Dr Rebecca B Perkins, Department of Obstetrics and Gynecology, Boston University School of Medicine/Boston Medical Center, 85 E Concord St 6th Floor, Boston, MA 02118, USA; rbperkin{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science.


The human papillomavirus (HPV) vaccination has been available worldwide since 2006 and over 170 million doses have been distributed. Although the HPV vaccination has demonstrated benefits in preventing precancerous lesions of the cervix, some parents forego vaccination due to safety concerns.1 While not commonly reported, concerns about neurological side effects have been aired in the media. Rigorous postmarketing analyses to assess for unintended sequelae of new medications are warranted and public concerns have prompted several high-quality studies assessing the HPV vaccine safety. Scheller and colleagues evaluated the incidence of multiple sclerosis (MS) and demyelinating diseases that could potentially …

View Full Text


  • Contributors RBP wrote the commentary and CLC contributed statistical expertise.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.